



CENTER FOR DRUG and HEALTH PLAN CHOICE

TO: Part D Plan Sponsors

FROM: Cynthia G. Tudor, Ph.D., Director, Medicare Drug Benefit and C & D Data Group

SUBJECT: MTMP Monitoring Evaluation-Update

DATE: April 3, 2009

This memo provides an update to the prior communication entitled “MTMP Monitoring Support Data Collection” sent on October 16, 2008 and provides additional information on the data collection process and deadlines for all sponsors with a CMS-approved Medication Therapy Management Program (MTMP). The purpose of the MTMP Monitoring Support contract is to monitor and evaluate MTMP information previously collected by sponsors. Sponsors are required to describe their methods of measuring outcomes for their program in their CMS-approved MTMP application. While sponsors collected these data for program years 2007 and 2008, this will be CMS’ first opportunity to monitor these data. Additionally, CMS will assess if sponsors have evaluated their MTMPs in compliance with the outcomes measures in their approved MTMP. Sponsors must complete the 2007 evaluation form by **July 31, 2009** and must complete the 2008 evaluation form by **November 30, 2009**.

Objectives of MTMP Monitoring

As stated previously, CMS is continuing to monitor and evaluate MTMPs offered by Part D sponsors in an effort to identify and understand attributes of the MTMPs that may be most effective for Medicare. Additional objectives include:

- Ensure that sponsors are evaluating their programs in compliance with the outcome measures stated in their CMS-approved MTMP application;
- Identify standardized outcomes that could be measured by all Part D sponsors;
- Assist in identifying those MTMPs that demonstrate the greatest positive impact on medication use of Medicare beneficiaries.

CMS has entered into a MTMP Monitoring Support contract with Optimal Solutions Group, LLC (Optimal) to monitor MTMP data previously collected by sponsors. Optimal has developed a MTMP monitoring tool and data collection evaluation form. A pilot phase with a small number of sponsors was completed to test these processes. Based on the feedback from this pretest phase, improvements were made to the evaluation

form and tool. These will now be rolled out to all sponsors with a CMS-approved MTMP. All Part D sponsors are required to comply.

Part D Sponsor Requirements

For 2007 and 2008 MTM programs, Part D sponsors are required to complete an evaluation form at the contract level via the web-based MTMP monitoring tool. The evaluation form will collect data already collected by sponsors including:

- Details related to the type, frequency, and recipient of their MTMP interventions;
- Details related to their MTMP outcomes measured;
- Specific MTMP outcomes data and measurements (aggregate).

Sponsors must complete the 2007 evaluation form by **July 31, 2009** and must complete the 2008 evaluation form by **November 30, 2009**. Failure to comply could result in compliance actions by CMS.

Access to MTMP Monitoring Tool

Sponsors will receive communications directly from Optimal with the web address of the monitoring tool and an individual respondent ID and password. These communications will come from mtmp@optimalsolutionsgroup.com. Each organization's contract will receive an e-mail from Optimal that contains a link to an evaluation form and a respondent ID specific to that contract. Communications will be sent to the Medicare Compliance Officer to delegate access. Sponsors must use the respondent ID, password, and evaluation form link provided in the invitation email to log into the monitoring tool. By using individual respondent IDs, sponsors will have the opportunity to save their progress and finish their data reporting at a later time.

The web-based monitoring tool will be password protected, and will only be accessible to users who have been invited to provide the data. Respondents will not be able to view responses of other sponsors. The data files will be hosted on Optimal's password-protected server. Access to the data will be limited to members of the analysis and reporting team.

Any general questions related to this MTMP Monitoring Support effort should be sent via email to Michelle Ketcham, PharmD, MBA at michelle.ketcham@cms.hhs.gov.